Johnson & Johnson announces positive clinical trial results for plaque psoriasis treatment
Johnson & Johnson (J&J) announced results from the phase 3 investigational study of its targeted oral peptide icotrokinra for treating plaque psoriasis. Within six months of starting the treatment,...















